J0752 HCPCS Level II code: Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J0752 is the HCPCS code for “Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0752Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
Short description: Hiv prep, oral lenacapavir
HCPCS · United States
Medicare details
The indicators CMS publishes with J0752 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Other carrier priced
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Coverage statute
- 1861 ddd
- Added
- Oct 1, 2025
Where J0752 sits
- 1J codesDrugs administered other than orally
- 2Active code J0752Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0752 mean?
J0752 is the HCPCS code for “Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0752?
CMS lists J0752’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Other carrier priced”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0752
All J codesJ0742Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mgJ0743Injection, cilastatin sodium; imipenem, per 250 mgJ0744Injection, ciprofloxacin for intravenous infusion, 200 mgJ0745Injection, codeine phosphate, per 30 mgJ0750Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)J0751Emtricitabine 200mg and tenofovir alafenamide 25mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)J0759Injection, clevidipine butyrate, 1 mgJ0760Injection, colchicine, per 1 mgJ0770Injection, colistimethate sodium, up to 150 mgJ0775Injection, collagenase, clostridium histolyticum, 0.01 mgJ0780Injection, prochlorperazine, up to 10 mgJ0791Injection, crizanlizumab-tmca, 5 mg